Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

NCT05416762 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder (MDD

Interventions

DRUG: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg
DRUG: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg
DRUG: Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg

Sponsor

Seasons Biotechnology (Taizhou) Co., Ltd.